NCT00406757 - Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2006

Primary Completion Date

July 15, 2009

Study Completion Date

July 15, 2009

Conditions

Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic

Interventions

DRUG

Nelarabine injection 400mg/m2

"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."

DRUG

Nelarabine injection 650mg/m2

Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.

DRUG

Nelarabine injection 1000mg/m2

"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."

DRUG

Nelarabine injection 1500mg/m2

Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.

Trial Locations (3)

460-0001

GSK Investigational Site, Aichi

104-0045

GSK Investigational Site, Tokyo

104-8560

GSK Investigational Site, Tokyo